Patients must have an estimated survival greater or equal to 3 monthsXx_NEWLINE_xXGrade 2 or greater rash of any cause at time of study entryXx_NEWLINE_xXGrade 2 or greater diarrhea of any cause at time of study entryXx_NEWLINE_xXAbsolute neutrophil count (ANC) greater than or equal to 1500/mm3 (greater than or equal to 1.5 X 103/uL)Xx_NEWLINE_xXPlatelets greater than or equal to 100,000/mm3 (greater than or equal to 100 X 109/L)Xx_NEWLINE_xXHemoglobin greater than or equal to 9.0 g/dLXx_NEWLINE_xXPlatelet count equal to or greater than 150,000/mclXx_NEWLINE_xXPre-existing neuropathy greater than or equal to grade 2Xx_NEWLINE_xXANC must be greater than or equal to 1500/mm3,Xx_NEWLINE_xXHemoglobin must be greater than or equal to 9 g/dL.Xx_NEWLINE_xXParticipant must not have a prior grade greater than or equal to 3 immune-mediated neurotoxicity or pneumonitis while receiving immunotherapy.Xx_NEWLINE_xXPrior grade greater than or equal to 3 immune-mediated neurotoxicity or pneumonitis (or any other unresolved or symptomatic adverse event in the last 3 months) while receiving immunotherapy.Xx_NEWLINE_xXWithin 30 days prior to enrollment: Platelet count equal to or greater than 150,000/mclXx_NEWLINE_xXAbsolute neutrophil count (ANC) greater than or equal to 1500/mm3 (greater than or equal to 1.5 X 103/ul)Xx_NEWLINE_xXPlatelets greater than or equal to 100,000/mm3 (greater than or equal to 100 X 109/L)Xx_NEWLINE_xXHemoglobin greater than or equal to 9.0 g/dLXx_NEWLINE_xXGranulocytes greater than or equal to 1500/ulXx_NEWLINE_xXPrior external beam radiation therapy resulting in greater than 20% total bone marrow receiving greater than 20 GyXx_NEWLINE_xXNottingham grade 1-2. Specifically, nuclear and mitotic scores must be less than or equal to 2.Xx_NEWLINE_xXProteinuria greater than 2 grams/24 hours.Xx_NEWLINE_xXThird or greater relapse.Xx_NEWLINE_xXHemoglobin (Hb) greater than or equal to 9.0 g/dLXx_NEWLINE_xXHemoglobin greater than or equal to 10 gram/deciliterXx_NEWLINE_xXSerum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 1.0 gram per deciliter (g/dL); orXx_NEWLINE_xXSubjects must have measurable disease by RECIST 1.1 criteria including one target tumor for injection. Superficial tumors must have one tumor greater than or equal to 1.0 cm, deep tumors greater than or equal to 1.0 cm (as measured by caliper (for non-injected tumors only) or image guidance);Xx_NEWLINE_xXPatient may not have severe hepatic disease (direct bilirubin greater than 3 mg/dl OR aspartate aminotransferase [AST] greater than 500 IU/L), unless hepatic injury is due to LCHXx_NEWLINE_xXThe presence of known lung or liver metastases greater than 1.0 cm in the long axis diameterXx_NEWLINE_xXThe presence of lymphadenopathy greater than 3 cm in the short-axis diameterXx_NEWLINE_xXSupplementation with vitamin E greater than 100% of the daily recommended doseXx_NEWLINE_xXSubject in whom all visible vessels or suture holes greater than or equal to 2mm in diameter have been ligated;Xx_NEWLINE_xXSerum creatinine equal or greater than 2.5 mg/deciliterXx_NEWLINE_xXAny of the following will exclude patients from the high-dose aldesleukin arm, but may be eligible for the low-dose aldesleukin arm:\r\n* Greater than 2 invasive thoracic procedures\r\n* Poor exercise tolerance\r\n* Greater than 66 years of ageXx_NEWLINE_xXCumulative anthracycline exposure greater than 450mg/m^2 doxorubicin equivalents prior to enrollmentXx_NEWLINE_xXPART I: Greater than or equal to 1 week since standard or investigational treatment for metastatic diseaseXx_NEWLINE_xXPART II: Greater than or equal to 1 week since receipt of standard or investigational HER2-directed therapy for metastatic or recurrent diseaseXx_NEWLINE_xXNormal prothrombin time (less than or equal to 15.2 seconds)Xx_NEWLINE_xXPrior myeloablative transplant containing full dose TBI (greater than 8 Gray [Gy])Xx_NEWLINE_xXPatients who have had less than or equal to 5 metastases treated with SRS are eligible.Xx_NEWLINE_xXBilirubin less than or equal to 2.0 mg/dL (unless considered tumor related)Xx_NEWLINE_xXActive alcohol use disorder or hazardous drinking; this will be screened with the Alcohol Use Disorders Identification Test (AUDIT-C), and positive scores (4 or greater for men and 3 or greater for women) will result in study clinician assessment and discretionXx_NEWLINE_xXThe time from the end of last induction, re-induction, or consolidation regimen should be greater than or equal to 14 daysXx_NEWLINE_xXClinically or radiologically measureable disease in the breast after diagnostic biopsy, defined as longest diameter greater than or equal to 25 mm (2.5cm)Xx_NEWLINE_xXKarnofsky equal or greater than 70Xx_NEWLINE_xXBody surface area (BSA) greater than 0.3 m^2Xx_NEWLINE_xXBody weight of greater than or equal to (>=) 39 kilogram (kg) at ScreeningXx_NEWLINE_xXSerum bilirubin less than or equal to 1.5 x ULN (CTCAE v3.0 grade 1)Xx_NEWLINE_xXExpected survival must be greater than three monthsXx_NEWLINE_xXMust have a Functional Performance Status of less than or equal to 2 on the ECOG scale (Appendix VII).Xx_NEWLINE_xXDisseminated extra-peritoneal or solid organ metastases\r\n* Includes carcinomatosis associated with clinically or radiographically evident ascites (greater than 500 cc)\r\n* Excludes greater omentum and ovarian metastasesXx_NEWLINE_xXPatients must have elevated calcitonin levels greater than 40 pg/mLXx_NEWLINE_xXRoom air oxygen saturation of 92% or greaterXx_NEWLINE_xXNormal cardiac ejection fraction (greater than or equal to 50% by echocardiography) and no evidence of hemodynamically significant pericardial effusion as determined by an echocardiogram within 4 weeks of the start of the treatment protocolXx_NEWLINE_xX>= 1 tumor site must have demonstrated uptake equal to or greater than normal liver as documented by nuclear scan imagingXx_NEWLINE_xXSubjects with hemoglobin values at the screening visit equal to or greater than 12.0 g/dLXx_NEWLINE_xXNo prior use of ketoconazole for greater than 7 daysXx_NEWLINE_xXBe greater than or equal to (>=) 16 years of age at the time of consent.Xx_NEWLINE_xXAny active acute GVHD or chronic GVHD greater than grade 1Xx_NEWLINE_xXChronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) or omega-3 free fatty acid supplementation within the last 60 days (defined as greater than or equal to 7 consecutive days)Xx_NEWLINE_xXPatients with greater than grade 2 hearing lossXx_NEWLINE_xXTarget lesions greater than 10 cmXx_NEWLINE_xXCerebral edema, grade 3 or greater prior to surgeryXx_NEWLINE_xXHemoglobin greater than or equal to 8.0 g/dLXx_NEWLINE_xXPlatelets greater than or equal to 75 x 10^9/LXx_NEWLINE_xXPatient must have a graded prognostic assessment (GPA) score 0.5 or greaterXx_NEWLINE_xXBilirubin less than or equal to 2.0 mg/dL (unless considered tumor related)Xx_NEWLINE_xXPatients have received a cumulative dose of doxorubicin of greater than 360 mg/m^2 or epirubicin of greater than 640 mg/m^2Xx_NEWLINE_xXBrain lesion(s) greater than 5 cm in diameterXx_NEWLINE_xXAge greater than or equal to 16 years oldXx_NEWLINE_xX3 or fewer brain metastases; Note: if lesions are symptomatic or greater than or equal to 1 cm each, these lesions must have been treated and stable for 3 months for the patient to be eligibleXx_NEWLINE_xXLess than or equal to 40 kgXx_NEWLINE_xXThe risk of disease recurrence with a five (5) year time period, as estimated by the treating physician, must be greater than or equal thirty percent (30%)Xx_NEWLINE_xXRoom air oxygen saturation of 92% or greaterXx_NEWLINE_xXNormal cardiac ejection fraction (greater than or equal to 55% by echocardiography) and no evidence of hemodynamically significant pericardial effusion as determined by an echocardiogram within 4 weeks of the start of the treatment protocolXx_NEWLINE_xXStable and/or decreasing dose of corticosteroids for greater than or equal to 7 days.Xx_NEWLINE_xXCreatinine of less than or equal to 1.7 gm/dLXx_NEWLINE_xXExpected survival must be greater than 3 monthsXx_NEWLINE_xXPatients who have received a cumulative dose of doxorubicin of greater than 360 mg/m^2 or epirubicin of greater than 640 mg/m^2Xx_NEWLINE_xXProstate volume greater than 80 cc on transrectal ultrasoundXx_NEWLINE_xXAnticipated lifespan greater than 12 weeksXx_NEWLINE_xXExpectation that we can obtain about 10 million blasts from blood and/or marrow (e.g., circulating blast count of 5,000 or greater or cellular marrow with greater than or equal to 20% blasts)Xx_NEWLINE_xXExpected survival is greater than 100 daysXx_NEWLINE_xXParticipants who are either refractory to or relapsed within 90 days of receiving a regimen containing a cumulative dose of greater than or equal to (>/=) 18 g/m^2 of cytarabineXx_NEWLINE_xXPatients must weigh greater than 30 kgXx_NEWLINE_xXHemoglobin greater than or equal to 8 g/dLXx_NEWLINE_xXHemoglobin greater than or equal to 9 g/dLXx_NEWLINE_xXBaseline albumin greater than or equal to Lower Limit of NormalXx_NEWLINE_xXAmerican Society of Anesthesiologists (ASA) class 4 or greaterXx_NEWLINE_xXMust weigh greater than or equal to 20 kg.Xx_NEWLINE_xXParticipants less than or equal to 16 years of age: Lansky greater than or equal to 50Xx_NEWLINE_xXParticipants greater than 16 years of age: Karnofsky greater than or equal to 50 or Eastern Cooperative Oncology Group (ECOG) less than 3.Xx_NEWLINE_xXPrior cumulative dose of doxorubicin of greater than 360 mg/m^2 or epirubicin of greater than 640 mg/m^2Xx_NEWLINE_xXSubject has a grade II or greater peripheral vascular diseaseXx_NEWLINE_xXHemoglobin greater than or equal to 8.0 g/dLXx_NEWLINE_xXBilirubin less than or equal to 1.5 x ULN (CTCAE v4 grade 1)Xx_NEWLINE_xXabsolute neutrophil count (ANC) greater than or equal to 1.0 x 10^9/L (for Cohorts 3A and 3B leucocyte count greater than or equal to 2 x 10^9/L; participants with bone marrow involvement should have ANC greater than or equal to 0.8 x 10^9/L and leucocyte count greater than or equal to 1 x 10^9/L).Xx_NEWLINE_xXPrevious treatment with ifosfamide and Grade greater than or equal to 3 nephrotoxicity or encephalopathy (Cohorts 3A and 3B).Xx_NEWLINE_xXAt the time of study enrollment patients must have a life expectancy of greater than or equal to 2 months; neurologic deficits in patients with CNS tumors must have been relatively stable for a minimum of 1 week prior to study enrollmentXx_NEWLINE_xXSmoking 5 or more cigarettes, little cigars and/or cigarillos per day, on average, within the 2 months preceding the screening visit and expired carbon monoxide (CO) greater than or equal to 6 parts per million (ppm) (if less than or equal to 5, then NicAlert Strip > 2)Xx_NEWLINE_xXhemoglobin must be greater than or equal to 9 g/dL. (Note: Patient must have discontinued growth factors greater than or equal to two weeks prior to entry labs.)Xx_NEWLINE_xXPersistent greater than or equal to grade 2 diarrhea regardless of etiology.Xx_NEWLINE_xXProduce an expired carbon monoxide (CO) level greater than or equal to 6 parts per million (ppm) or a NicAlert reading of > 2Xx_NEWLINE_xXKarnofsky greater than or equal to 80%Xx_NEWLINE_xXBilirubin less than or equal to 2.0 mg/dL (unless considered tumor related)Xx_NEWLINE_xXHemoglobin greater than or equal to 8.0Xx_NEWLINE_xXANC greater than or equal to 500 (7 days after last dose of growth factor)Xx_NEWLINE_xXNo hematuria and/or proteinuria greater than 1+ on urinalysisXx_NEWLINE_xXRenal insufficiency, with creatinine greater than 1.5 mg/mLXx_NEWLINE_xXProthrombin time (PT) no greater than 6 seconds longer than control.Xx_NEWLINE_xXLess than or equal to 10 pack years of tobacco historyXx_NEWLINE_xXPatients with untreated AML must meet at least one of the following conditions:\r\n* Age greater than or equal to 75 years;\r\n* Age greater or equal to 60 and less than 75 years with at least one of the following poor prognostic factors:\r\n** Secondary AML, as determined by known and documented exposure to chemotherapy or radiation therapy\r\n** Antecedent history of MDS or myeloproliferative disorder according to WHO criteria for at least 3 months prior to trial entry;\r\n** Unfavorable cytogenetic abnormalities including chromosome 5 and 7 as well as complex;\r\n** ECOG performance status 2Xx_NEWLINE_xXChronic usage of aspirin greater than 81 mg/dayXx_NEWLINE_xXHemoglobin greater than or equal to 8.0 g/dl (Turnstile II)Xx_NEWLINE_xXNewly diagnosed MCL: Ki-67 to be equal or more than 50%Xx_NEWLINE_xXSerum creatinine less than or equal to 1.5 in males, or 1.4 in femaleXx_NEWLINE_xXHemoglobin greater than or equal to 8.0 g/dl (Turnstile II)Xx_NEWLINE_xXLess than or equal to (</=) 96 hours between onset of ILI and first dose of study drugXx_NEWLINE_xXDirect bilirubin equal to or less than 1.5 x ULN; or equal to or less than 2 x ULN (if upon judgment of the treating physician, it is believed to be due to extramedullary hematopoiesis related to MF)Xx_NEWLINE_xXStable hemoglobin greater than or equal to 8.0 g/dlXx_NEWLINE_xXInclusion Criteria:\n\n        Participants must meet all of the following criteria to be included in the study:\n\n          1. Age greater than or equal to 18 years.\n\n          2. Histopathologic diagnosis of CTCL (mycosis fungoides [MF] or Sezary Syndrome [SS]),\n             confirmed by skin biopsy, or lymph node, or blood assessment, of current disease.\n\n          3. CD25 assay-positive tumor, defined as detectable CD25 on greater than or equal to 20%\n             of total lymphoid infiltrate in biopsied skin lesions by immunohistochemistry.\n\n          4. CTCL disease stage at study entry as follows, according to ISCL/EORTC (Olsen 2011).\n\n               -  Lead-In Phase: Stage IA - IV, except participants with CNS involvement.\n\n               -  Main Study: Stage IA - IVA2 including lymph node disease N2 and N3\n\n          5. History of prior therapies for CTCL as follows: must have had prior therapy, any\n             number of prior therapies allowed.\n\n             Topical treatments (except topical chemotherapy) and steroids are not considered as\n             prior therapies.\n\n          6. A minimum washout period of 4 weeks after previous CTCL therapy is recommended before\n             the first dose of E7777.\n\n             Participants must have recovered from any adverse effects from any previous CTCL\n             therapy to CTCAE Grade <2 before starting study drug. A shorter washout may be allowed\n             if participant is experiencing progressive disease despite ongoing treatment\n\n          7. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 in the Lead-In\n             Phase and performance status of 0 or 1 in the Main Study.\n\n          8. Life expectancy greater than or equal to 3 months in the Lead-In Phase and greater\n             than or equal to 12 months in the Main Study.\n\n          9. Adequate bone marrow reserves as evidenced by:\n\n               -  platelets greater than or equal to 100,000/mm3 (100 x 10^9/L)\n\n               -  clinically stable hemoglobin greater than or equal to 9 g/dL (90 g/L) and\n                  hematocrit greater than or equal to 27% without transfusion support\n\n         10. Normal hepatic function as evidenced by:\n\n               -  bilirubin and alkaline phosphatase less than or equal to 1 x the upper limit of\n                  normal (ULN).\n\n               -  aspartate aminotransferase (AST) less than or equal to 75 U/L and alanine\n                  aminotransferase (ALT) less than or equal to 100 U/L.\n\n               -  albumin greater than or equal to 3.0 g/dL (30 g/L).\n\n         11. Adequate renal function as evidenced by serum creatinine less than or equal to 1.8\n             mg/dL (158 umol/L) OR calculated creatinine clearance greater than or equal to 50\n             mL/min (per the Cockcroft-Gault formula) with less than 2+ protein OR 24- hour urine\n             creatinine clearance greater than or equal to 50 mL/minute with 24- hour urine protein\n             less than 1g.\n\n         12. Provide written informed consent prior to any study-specific screening procedures.\n\n         13. Females may not be lactating or pregnant at Screening or Baseline\n\n         14. All females will be considered to be of childbearing potential unless they are\n             postmenopausal or have been sterilized surgically\n\n         15. Male participants must have had a successful vasectomy (confirmed azoospermia) or they\n             and their female partner must meet the criteria above\n\n        Exclusion Criteria\n\n        Participants who meet any of the following criteria will be excluded from the study:\n\n          1. Prior denileukin diftitox therapy\n\n          2. Use of topical steroids within 14 days of Day 1 of initial therapy is not allowed\n\n          3. Active malignancy (except for CTCL, definitively treated basal or squamous cell\n             carcinoma of the skin, and carcinoma in-situ of the cervix) within the past 24 months.\n\n          4. Serious intercurrent illness\n\n          5. Significant cardiac disease requiring ongoing treatment, including congestive heart\n             failure (CHF), severe coronary artery disease (CAD), cardiomyopathy, uncontrolled\n             cardiac arrhythmia, unstable angina pectoris, or myocardial infarction (MI)\n\n          6. Significant pulmonary symptoms or disease\n\n          7. History of uncontrolled seizure disorder or active central nervous system disease\n\n          8. Major surgery within 2 weeks of study enrollment\n\n          9. Significant or uncontrolled infections requiring specific anti-infective therapy\n\n         10. Known human immunodeficiency virus (HIV) infection; known active hepatitis B or\n             hepatitis C infection\n\n         11. Females who are pregnant (positive urine test) or breastfeeding\n\n         12. Any history of a medical condition or a concomitant medical condition that, in the\n             opinion of the investigator, would compromise the participant's ability to safely\n             complete the study.Xx_NEWLINE_xXCreatinine less than or equal to 2.0 unless related to the diseaseXx_NEWLINE_xXBilirubin less than or equal to 3.0Xx_NEWLINE_xXPatients with severe hepatic disease (direct bilirubin greater than 3 ug/dl or serum glutamic pyruvate transaminase [SGPT] greater than 500 ug/dl)Xx_NEWLINE_xXAbsolute neutrophil count greater than or equal to 750/mm^3 (Turnstile II - Chemotherapy/Cell\r\nInfusion- Inclusion Criteria)Xx_NEWLINE_xXPlatelet count greater than or equal to 75,000/mm^3 (Turnstile II - Chemotherapy/Cell Infusion-Inclusion Criteria)Xx_NEWLINE_xXHemoglobin greater than or equal to 8.0 g/dl (Turnstile II - Chemotherapy/Cell Infusion)Xx_NEWLINE_xXB-cell cohort: Stage 1; ALL in second or greater relapse or refractory to 2 prior induction regimens with greater than or equal to (>=) 5 percent (%) blasts in the bone marrow and aged 1 to less than (<) 18 years. Stage 2; ALL in second or greater relapse or refractory to 2 prior induction regimens with (>=) 5% blasts in the bone marrow and aged 1 to 30 years. LL in second or greater relapse or refractory to 2 prior induction regimens and biopsy proven and with evidence of measurable disease by radiologic criteria and aged 1 to 30 years.Xx_NEWLINE_xXBody weight of greater than or equal to (>=) 39 kilogram (kg) at ScreeningXx_NEWLINE_xXEvidence of cirrhosis, documented by one of the following: Liver biopsy histologic diagnosis: Metavir Score greater than 3 (includes 3 - 4 or ¾) or Ishak score greater than 4 In the absence of liver biopsy: a FibroScan score greater than or equal to 12.5 kPa or Fibrotest score of >0.75 AND an APRI score greater than 1.5Xx_NEWLINE_xXBody weight of greater than 30 kgXx_NEWLINE_xXANC must be greater than or equal to 1500/mm3Xx_NEWLINE_xXHemoglobin must be greater than or equal to 9 g/dL.Xx_NEWLINE_xXPatients with chronic diarrhea or with Grade 2 or greater diarrhea despite appropriate medical management.Xx_NEWLINE_xXPatients with chronic diarrhea or with Grade 2 or greater diarrhea despite appropriate medical management.Xx_NEWLINE_xXSubjects previously treated with enzyme-induced antiepileptic drugs (EIAEDs) must have discontinued treatment with these agent(s) greater than or equal to 2 weeks prior to enrollment.Xx_NEWLINE_xXAge greater than or equal to 15 yearsXx_NEWLINE_xXGreater than or equal to 6 weeks since the receipt of chemotherapy or radiation therapyXx_NEWLINE_xXInclusion Criteria:\n\n        The tumor tissue must have been determined to be KRAS, NRAS, BRAF, PIK3CA (all RAS\n        quadruple) wild-type by CLIA testing.\n\n        The ECOG performance status must be 0, 1 or 2. Patients must have the ability to swallow\n        and retain oral medication. There must be documentation by CT scan, or MRI, that the\n        patient has evidence of measurable metastatic disease per RECIST 1.1 criteria.\n\n        Patients must have an accessible metastatic lesion for pretreatment core biopsy\n        procurement.\n\n        Unless either drug is medically contraindicated, patients must have received oxaliplatin\n        and irinotecan as part of standard chemotherapy regimens. (This includes adjuvant therapy.)\n\n        Specific patient eligibility for quadruple WT and HER2 status:\n\n        Arm 1:\n\n        HER2 amplified confirmed by CLIA testing performed on blood samples, and prior treatment\n        with cetuximab or panitumumab.\n\n        HER2 mutation confirmed by CLIA testing of tumor, and with or without prior treatment with\n        cetuximab or panitumumab.\n\n        Arm 2:\n\n        HER2 WT or HER2 amplified confirmed by CLIA testing of this tumor, and no prior therapy\n        with cetuximab or panitumumab.\n\n        Blood counts performed within 2 weeks prior to study entry must meet the following\n        criteria:\n\n        ANC must be greater than or equal to 1000/mm3. Platelet count must be greater than or equal\n        to 75,000/mm3. Hemoglobin must be greater than or equal to 8 g/dL.\n\n        Adequate hepatic function performed within 2 weeks prior to study entry must be met:\n\n          -  Total bilirubin must be less than or equal to 1.5 x ULN (upper limit of normal) for\n             the lab unless the patient has a bilirubin elevation greater than 1.5 x ULN to 3 x ULN\n             due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin;\n             and\n\n          -  Alkaline phosphatase must be less than or equal to 3 x ULN for the lab with the\n             following exception: for patients with documented liver metastases or bone involvement\n             alkaline phosphatase must be less than or equal to 5 x ULN; and\n\n          -  AST and ALT must be less than or equal to 3 x ULN for the lab with the following\n             exception: for patients with documented liver metastases, AST and ALT must be less\n             than or equal to 5 x ULN.\n\n        Serum creatinine performed within 2 weeks prior to study entry must be less than or equal\n        to 1.5 x ULN for the lab.\n\n        Patients eligible for Arm 1 (neratinib + trastuzumab): Left ventricular ejection fraction\n        must be greater than or equal to 50% or within normal range for the institution (whichever\n        is lowest).\n\n        Female patients and male patients with female partners of reproductive potential must agree\n        to use an effective method of contraception during therapy and for at least 7 months after\n        the last dose of study therapy.\n\n        Exclusion Criteria:\n\n        Diagnosis of anal or small bowel carcinoma. Colorectal cancer histology other than\n        adenocarcinoma, e.g., sarcoma, lymphoma, carcinoid.\n\n        Previous therapy with any HER2 targeting agents (such as trastuzumab, lapatinib, neratinib,\n        etc.) for any malignancy.\n\n        Symptomatic brain metastases or brain metastases requiring chronic steroids to control\n        symptoms.\n\n        Active hepatitis B or hepatitis C with abnormal liver function tests. Malabsorption\n        syndrome, ulcerative colitis, inflammatory bowel disease, resection of the stomach or small\n        bowel, or other disease or condition significantly affecting gastrointestinal function.\n\n        Persistent CTCAE v4.0 greater than or equal to grade 2 diarrhea regardless of etiology.\n\n        CTCAE v4.0 grade 3 or 4 anorexia or nausea related to metastatic disease. CTCAE v4.0\n        greater than or equal to grade 2 vomiting related to metastatic disease.\n\n        Any of the following cardiac conditions: documented congestive heart failure; myocardial\n        infarction within 6 months prior to study entry; unstable angina within 6 months prior to\n        study entry; symptomatic arrhythmia.\n\n        Serious or non-healing wound, skin ulcer, or bone fracture. History of bleeding diathesis.\n        (Patients on stable anticoagulant therapy are eligible.) Symptomatic interstitial lung\n        disease or definitive evidence of interstitial lung disease described on CT scan, MRI, or\n        chest x-ray in asymptomatic patients; dyspnea at rest requiring current continuous oxygen\n        therapy.\n\n        Previous serious hypersensitivity reaction to monoclonal antibodies. (Determination of\n        \serious\ hypersensitivity reaction is at the investigator's discretion.) Other\n        malignancies unless the patient is considered to be disease-free and has completed therapy\n        for the malignancy greater than or equal to 12 months prior to study entry. Patients with\n        the following cancers are eligible if diagnosed and treated within the past 12 months:\n        carcinoma in situ of the cervix, colorectal carcinoma in situ, melanoma in situ, and basal\n        cell and squamous cell carcinoma of the skin.\n\n        Psychiatric or addictive disorders or other conditions that, in the opinion of the\n        investigator, would preclude the patient from meeting the study requirements.\n\n        Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing should be\n        performed within 14 days prior to study entry according to institutional standards for\n        women of childbearing potential.) Use of any investigational agent within 4 weeks prior to\n        study entry. Note: Use of agents known to be strong cytochrome P450 (CYP) 3A4 inducers or\n        inhibitors, and proton pump inhibitors (PPIs) should be avoided for the duration of study\n        therapy.Xx_NEWLINE_xXPatients who have proteinuria CTCAE version (v)4.03 grade 2 or greater within < 30 days of registrationXx_NEWLINE_xXExpected survival of greater than 16 weeks.Xx_NEWLINE_xXHematocrit (Hct) less than or equal to 24%Xx_NEWLINE_xXBilirubin greater than or equal to 2.0 x ULNXx_NEWLINE_xXAnticipated lifespan greater than 3 monthXx_NEWLINE_xXKPS equal to or greater than 70Xx_NEWLINE_xXEach lesion must be less than or equal to 5 cm in maximal diameter and multiple lesions must be less than or equal to 18 cm for the sum of the diameters in 3 dimensions; Example: 3 lesions each 2 + 2 + 2 cm have an aggregate diameter of 18 cm which is acceptableXx_NEWLINE_xXPatients with a history of malignancy that has been completely treated, with no\n             evidence of that cancer currently, are permitted to enrol in the trial provided all\n             chemotherapy was completed greater than 6 months prior and/or bone marrow transplant\n             greater than 2 years priorXx_NEWLINE_xXPatients with severe hepatic disease (direct bilirubin greater than 3 mg/dl or aspartate aminotransferase [AST] greater than 500 IU/L)Xx_NEWLINE_xXPatients with tumors with anticipated transurethral resection time greater than 1 hourXx_NEWLINE_xXGrade 2 or greater diarrheaXx_NEWLINE_xXNormal cardiac ejection fraction (greater than or equal to 50% by echocardiography) and no evidence of hemodynamically significant pericardial effusion as determined by an echocardiogram within 6 weeks of the start of the treatment protocolXx_NEWLINE_xXInclusion Criteria\n\n          1. Signed written informed consent must be obtained and documented according to\n             International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP), the\n             local regulatory requirements, and permission to use private health information in\n             accordance with the Health Insurance Portability and Accountability Act (HIPPA) prior\n             to study-specific screening procedures\n\n          2. For solid tumors or lymphoma, a histologically or cytologically confirmed solid tumor\n             that is metastatic, unresectable, or recurrent and for which standard curative or\n             palliative therapies do not exist or are no longer effective.\n\n          3. ? 18 years of age\n\n          4. For solid tumors, measurable disease as defined by Response Evaluation Criteria in\n             Solid Tumors (RECIST 1.1)\n\n          5. For lymphoma, measurable disease as defined by the International Workshop to\n             Standardize Response Criteria for Non-Hodgkin's Lymphoma\n\n          6. For multiple myeloma, measurable disease as defined by the International Uniform\n             Response Criteria for Multiple Myeloma\n\n          7. Karnofsky performance status greater than or equal to 70%\n\n          8. Male or female patients of child-producing potential must agree to use contraception\n             or avoidance of pregnancy measures during the study and for 30 days after the last\n             BBI608 dose\n\n          9. Females of childbearing potential must have a negative serum pregnancy test\n\n         10. Aspartate transaminase (AST) and alanine transaminase (ALT) less than or equal to 1.5\n             × upper limit of normal(ULN)\n\n         11. Hemoglobin (Hgb) greater than or equal to 10 g/dl\n\n         12. Total bilirubin less than or equal to 1.5 × ULN\n\n         13. Creatinine less than or equal to 1.5 x ULN or creatinine clearance greater than 60\n             mL/min/1.73 m2 for patients with creatinine levels above institutional normal.\n             Creatinine < 2.5 x ULN for multiple myeloma patients.\n\n         14. Absolute neutrophil count greater than or equal to 1.5 x 109/L\n\n         15. Platelets greater than or equal to 100 x 109/L\n\n         16. Life expectancy greater than or equal to 3 months\n\n        Exclusion Criteria\n\n          1. Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents\n             within four weeks of first dose with the exception for a single dose radiation up to\n             8 Gray (equal to 800 RAD) with palliative intent for pain control up to 14 days\n             before beginning the administration of BBI608.\n\n          2. Surgery within 4 weeks prior to first dose\n\n          3. Any known untreated brain metastases. Treated subjects must be stable for 4 weeks\n             after completion of that treatment, with image documentation required. Patients must\n             have no clinical symptoms from brain metastases and must be either off steroids or on\n             a stable dose of steroids for at least 2 weeks prior to protocol enrollment. Patients\n             with known leptomeningeal metastases are excluded, even if treated.\n\n          4. Pregnant or breastfeeding\n\n          5. Significant gastrointestinal disorder(s), in the opinion of the Principal\n             Investigator, (e.g., Crohn's disease, ulcerative colitis, extensive gastric and small\n             intestine resection)\n\n          6. Unable or unwilling to swallow BBI608 capsules daily\n\n          7. Uncontrolled intercurrent illness including, but not limited to ongoing or active\n             infection, clinically significant non-healing or healing wounds, symptomatic\n             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant\n             pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled\n             infection or psychiatric illness/social situations that would limit compliance with\n             study requirementsXx_NEWLINE_xXInclusion Criteria\n\n          1. Signed written informed consent must be obtained and documented according to\n             International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP), the\n             local regulatory requirements, and permission to use private health information in\n             accordance with the Health Insurance Portability and Accountability Act (HIPPA) prior\n             to study-specific screening procedures\n\n          2. For solid tumors or lymphoma, a histologically or cytologically confirmed solid tumor\n             that is metastatic, unresectable, or recurrent and for which standard curative or\n             palliative therapies do not exist or are no longer effective.\n\n          3. ? 18 years of age\n\n          4. For solid tumors, measurable disease as defined by Response Evaluation Criteria in\n             Solid Tumors (RECIST 1.1)\n\n          5. For lymphoma, measurable disease as defined by the International Workshop to\n             Standardize Response Criteria for Non-Hodgkin's Lymphoma\n\n          6. For multiple myeloma, measurable disease as defined by the International Uniform\n             Response Criteria for Multiple Myeloma\n\n          7. Karnofsky performance status greater than or equal to 70%\n\n          8. Male or female patients of child-producing potential must agree to use contraception\n             or avoidance of pregnancy measures during the study and for 30 days after the last\n             BBI608 dose\n\n          9. Females of childbearing potential must have a negative serum pregnancy test\n\n         10. Aspartate transaminase (AST) and alanine transaminase (ALT) less than or equal to 1.5\n             × upper limit of normal(ULN)\n\n         11. Hemoglobin (Hgb) greater than or equal to 10 g/dl\n\n         12. Total bilirubin less than or equal to 1.5 × ULN\n\n         13. Creatinine less than or equal to 1.5 x ULN or creatinine clearance greater than 60\n             mL/min/1.73 m2 for patients with creatinine levels above institutional normal.\n             Creatinine < 2.5 x ULN for multiple myeloma patients.\n\n         14. Absolute neutrophil count greater than or equal to 1.5 x 109/L\n\n         15. Platelets greater than or equal to 100 x 109/L\n\n         16. Life expectancy greater than or equal to 3 months\n\n        Exclusion Criteria\n\n          1. Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents\n             within four weeks of first dose with the exception for a single dose radiation up to\n             8 Gray (equal to 800 RAD) with palliative intent for pain control up to 14 days\n             before beginning the administration of BBI608.\n\n          2. Surgery within 4 weeks prior to first dose\n\n          3. Any known untreated brain metastases. Treated subjects must be stable for 4 weeks\n             after completion of that treatment, with image documentation required. Patients must\n             have no clinical symptoms from brain metastases and must be either off steroids or on\n             a stable dose of steroids for at least 2 weeks prior to protocol enrollment. Patients\n             with known leptomeningeal metastases are excluded, even if treated.\n\n          4. Pregnant or breastfeeding\n\n          5. Significant gastrointestinal disorder(s), in the opinion of the Principal\n             Investigator, (e.g., Crohn's disease, ulcerative colitis, extensive gastric and small\n             intestine resection)\n\n          6. Unable or unwilling to swallow BBI608 capsules daily\n\n          7. Uncontrolled intercurrent illness including, but not limited to ongoing or active\n             infection, clinically significant non-healing or healing wounds, symptomatic\n             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant\n             pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled\n             infection or psychiatric illness/social situations that would limit compliance with\n             study requirementsXx_NEWLINE_xXPatient with severe hepatic disease (direct bilirubin greater than 3 mg/dl or aspartate aminotransferase [AST] greater than 500 IU/L)Xx_NEWLINE_xXCreatinine of less than or equal to 1.7 gm/dLXx_NEWLINE_xXCreatinine of less than or equal to 1.7 gm/dLXx_NEWLINE_xXHemoglobin greater than or equal to 8.0 g/dLXx_NEWLINE_xXDCIS must express estrogen and/or progesterone receptor, as determined by immunohistochemical methods on the diagnostic pathology sample, according to the local institution’s standard protocol; greater than or equal to 1% cells will be considered to be positiveXx_NEWLINE_xXBilirubin less than or equal to 1.5 (except if due to Gilbert's disease)Xx_NEWLINE_xXBilirubin less than or equal to 1.5 x ULN (CTEP CTCAE version 4.0, grade 1)Xx_NEWLINE_xXGranulocytes greater than or equal to 1500/ulXx_NEWLINE_xXPatients with the following ocular conditions: corneal disorders, monocular vision (i.e., best corrected visual acuity greater than or equal to 20/200 in one eye), or active ocular disorders requiring treatmentXx_NEWLINE_xXMeasurable splenomegaly prior to study entry as demonstrated by palpable spleen measuring greater than or equal to (>=) 5 cm below the left costal margin OR spleen volume of >= 450 cm^3 measured by MRIXx_NEWLINE_xXSubjects must have Eastern Cooperative Oncology Group (ECOG) Performance Status of ) to 2 for subjects greater than or equal to 75 years of age, or 0 to 3 for subjects greater than or equal to 60 to 74 years of ageXx_NEWLINE_xXHas unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any prior therapies.Xx_NEWLINE_xXIHC greater than or equal to 20 percent of tumor on tissue sections must stain with NPC-1C.Xx_NEWLINE_xXHemoglobin greater than or equal to 8.5 g/dL (may be receiving supportive therapy)Xx_NEWLINE_xXANC greater than or equal to 1,500 K/uLXx_NEWLINE_xXHave greater than grade 2 ascites at time of enrollment.Xx_NEWLINE_xXBiochemical recurrence: defined as a cancer antigen (CA)-125 greater than or equal to two times the upper normal limit; patients whose CA125 is less than 100 U/mL must undergo a second confirmatory value within a period of not more than 4 weeks; patients with a level greater than or equal to 100 U/mL may be entered without confirmatory measurementXx_NEWLINE_xXInternational Prognostic Index (IPI) of 2 or greaterXx_NEWLINE_xXPatients with the following ocular conditions: corneal disorders, monocular vision (ie. best corrected visual acuity greater than or equal to 20/200 in one eye), or active ocular disorders requiring treatmentXx_NEWLINE_xXhemoglobin must be greater than or equal to 9 g/dL.Xx_NEWLINE_xXPersistent CTCAE v4.0 greater than or equal to grade 2 diarrhea regardless of etiology.Xx_NEWLINE_xXAny significant bleeding (greater than or equal to grade 3, hemorrhage) that is not related to the primary colon tumor within 6 months before randomization.Xx_NEWLINE_xXunstable angina (angina symptoms at rest) within less than or equal to 3 months prior to randomization; andXx_NEWLINE_xXKPS 70% or greaterXx_NEWLINE_xXPatients deemed to have mild hepatic impairment should not be considered for this study; patients with a direct bilirubin level greater than 2.0 mg/dL at screening should be excludedXx_NEWLINE_xXParticipant has any of the following conditions: Non-secretory or oligo-secretory multiple myeloma, active plasma cell leukemia i.e., either 20% of peripheral white blood cells or greater than 2.0 X 10^9/liter (L) circulating plasma cells by standard differential, waldenstrom's macroglobulinemia, amyloidosis, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), known Human Immunodeficiency Viral (HIV) infection, active hepatitis B or C infection based on blood screen tests, significant cardiovascular disease, including uncontrolled angina, severe or uncontrolled arrhythmia, recent myocardial infarction within 6 months of randomization, or congestive heart failure New York Heart Association (NYHA) Class greater than or equal to 3, Major surgery within 4 weeks prior to randomization, acute infections requiring parenteral therapy (antibiotic, antifungal, or antiviral) within 14 days prior to randomization, peripheral neuropathy greater than or equal to Grade 3 or greater than or equal to Grade 2 with pain within 2 weeks prior to randomization, uncontrolled diabetes or uncontrolled hypertension within 14 days prior to randomization, any other medical condition that, in the opinion of the Investigator, would adversely affect the participant's participation in the studyXx_NEWLINE_xXAnticipated lifespan greater than 3 monthsXx_NEWLINE_xXAbsolute neutrophil count (ANC) greater than or equal to 750/mm3 (greater than or equal to 0.75 X 10^9/L)Xx_NEWLINE_xXPlatelets greater than or equal to 75,000/mm3 (greater than or equal to 75 X 10^9/L)Xx_NEWLINE_xXHemoglobin greater than or equal to 9.0 g/dLXx_NEWLINE_xXPatient’s with an International Metastatic Renal Cell Carcinoma Database Consortium (IMDC or Heng) score of 3 or less will be included; score greater than 4 will be excluded; 1 point each: requirement of systemic treatment for metastatic disease less than 1 year of original diagnosis of renal cell carcinoma, a serum calcium greater than 10, anemia, neutrophilia, thrombocytosis, ECOG performance status >= 2Xx_NEWLINE_xXFasting (greater than or equal to [>=] 8 hours) glucose less than or equal to (<=) 160 milligrams per deciliter (mg/dL)Xx_NEWLINE_xXUrinalysis with no greater than 1+ hematuria or proteinuriaXx_NEWLINE_xXHemoglobin greater than or equal to 9 g/dLXx_NEWLINE_xXHemoglobin greater than or equal to 9 g/dLXx_NEWLINE_xXSignificant obstructive symptoms (IPSS greater than 20)Xx_NEWLINE_xXInclusion Criteria:\n\n        1.18 years of age or older 2. Able to provide written informed consent or have their legal\n        representatives provide written informed consent 3. Documented histological or cytological\n        evidence of adenocarcinoma of the prostate. Subjects whose pathology reports are no longer\n        available may be enrolled if, in the opinion of the investigator, the subject has a\n        clinical course consistent with prostatic adenocarcinoma 4. ECOG Performance Status of 0 or\n        1 5. Undergone orchiectomy, or have ongoing LHRH analogue therapy prior to C1D1. Subjects\n        on LHRH analogues should remain on these agents for the duration of the study 6. Castrate\n        levels of testosterone less than or equal to 50 ng/dl (or 1.7 nmol/L) and have progressive\n        disease at Screening defined as PSA rise determined by a minimum of 2 rising PSA values\n        greater than or equal to 1 week between each assessment. The PSA value at the Screening\n        visit must be greater than or equal 2ng/mL with or without: Soft tissue disease progression\n        defined by RECIST 1.1 at Screening or less than or equal to 28 days of C1D1. Measurable\n        disease is not required for entry.\n\n        Lymph nodes greater than or equal to 1.5cm (short axis) are considered measurable disease\n        bone disease progression defined by greater than or equal 2 new lesions on bone scan at\n        Screening, or less than or equal 28 days of C1D1 7. Have received abiraterone and/or\n        enzalutamide. Subject must have received either abiraterone or enzalutamide for greater\n        than or equal to 12 weeks. Other second generation CYP17 inhibitors/androgen receptor\n        antagonists including but not limited to TAK-700 (orteronel), TOK-001 (galeterone) may have\n        been taken in place of abiraterone and ARN-509 (apalutamide) may have been taken in place\n        of enzalutamide.\n\n        8. Adequate hematopoietic function as evidenced by:\n\n          -  WBC greater than or equal to 3,000/?l\n\n          -  ANC greater than or equal to 1,500/?l\n\n          -  Platelet count greater than or equal to 100,000/?l\n\n          -  HGB greater than or equal to 10 g/dl and not transfusion dependent 9. Adequate liver\n             function, including all the following:\n\n          -  Total serum bilirubin less than or equal to 2.0 x ULN unless the subject has\n             documented Gilbert syndrome;\n\n          -  Aspartate and alanine aminotransferase (AST & ALT) less than or equal to 3.0 x ULN or\n             less than or equal to 5.0 x ULN if subject has liver metastasis;\n\n          -  Alkaline phosphatase less than or equal to 3.0 x ULN or less than or equal to 5 x ULN\n             in case of bone metastasis and/or hepatic metastasis 10. Subjects must have adequate\n             renal function as evidenced by a serum creatinine of less than or equal to 2.0 mg/dl\n             11. Potassium (K+) greater than or equal to 3.5 mEq/l 12. Subject and his female\n             partner who is of childbearing potential must use 2 acceptable methods of birth\n             control (one of which must include a condom as a barrier method of contraception)\n             starting at Screening and continuing throughout the study period and for 3 months\n             after final study drug administration.\n\n          -  Two acceptable forms of birth control include:\n\n               1. Condom (barrier method of contraception), and\n\n               2. One of the following:\n\n                    1. Oral, injected or implanted hormonal contraception\n\n                    2. Placement of an intrauterine device (IUD) or intrauterine system (ISU)\n\n                    3. Additional barrier methods of contraception: Occlusive cap (diaphragm or\n                       cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.\n\n                    4. Vasectomy or surgical castration greater than or equal to 6 months prior to\n                       Screening.\n\n             13. Able to swallow study medication 14. Able to comply with study requirements\n\n        Exclusion Criteria\n\n        Each subject eligible to participate in this study must not have any of the following:\n\n          1. Received sipuleucel-T (Provenge ®) treatment within 28 days of C1D1\n\n          2. Received 5-alpha reductase inhibitors such as finasteride (PROSCAR®, PROPECIA®), or\n             dutasteride (AVODART®) within 28 days of C1D1\n\n          3. Received any investigational agent less than or equal to 28 days of C1D1\n\n          4. Received palliative radiotherapy less than or equal to 2 weeks of C1D1\n\n          5. Symptomatic CNS metastases\n\n          6. History of another invasive malignancy less than or equal to 3 years of C1D1\n\n          7. A QTcF interval of greater than 470 msec; if the Screening ECG QTcF interval is\n             greater than 470 msec, it may be repeated, and if repeat less than or equal to 470\n             msec, the subject may be enrolled\n\n          8. Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, ventricular\n             fibrillation, torsades de pointes, second degree or third degree atrioventricular\n             heart block without a permanent pacemaker in place)\n\n          9. Started a bone modifying agent (e.g. bisphosphonates, denosumab) less than or equal to\n             28 days of C1D1 (note: ongoing bone modifying agents administered less than 28 days\n             are allowed)\n\n         10. Any medical condition that could preclude subject participation in the study, pose an\n             undue medical hazard, or which could interfere with study results\n\n         11. Class III or IV Congestive Heart Failure (CHF) as defined by the New York Heart\n             Association (NYHA) functional classification system within the previous 6 months\n\n         12. A history of loss of consciousness or transient ischemic attack less than or equal to\n             12 months of C1D1\n\n         13. Known active HIV, Hepatitis B, or Hepatitis C infections\n\n         14. Known or suspected hypersensitivity to seviteronel, or any components of the\n             formulation\n\n         15. Any other condition which in the opinion of the investigator would preclude\n             participation in the studyXx_NEWLINE_xXIpsilateral mammogram done greater than 6 months prior to studyXx_NEWLINE_xXThe lesion can be accurately measured in at least one dimension as greater than or equal to 1.0 cm (viable tumor for typical; and longest diameter for atypical), andXx_NEWLINE_xXNonhepatic lesion c. Lymph node (LN) lesion that measures at least one dimension as greater than or equal to 1.5 cm in the short axis, except for porta hepatis LN that measures greater than or equal to 2.0 cm in the short axis d. Non-nodal lesion that measures greater than or equal to 1.0 cm in the longest diameter Lesions previously treated with radiotherapy or locoregional therapy must show radiographic evidence of disease progression to be deemed a target lesion.Xx_NEWLINE_xXHemoglobin (Hb) greater than or equal to 8.5 g/dLXx_NEWLINE_xXHCC with greater than or equal to 50 percent liver occupationXx_NEWLINE_xXProstate gland volume should be no greater than 70 cc, volumetrically measured.Xx_NEWLINE_xXPatients must have an interval of greater than or equal to 60 days from the completion of radiation therapy to study entryXx_NEWLINE_xXHematocrit of greater than 30%Xx_NEWLINE_xXProteinuria CTCAE grade 2 or greaterXx_NEWLINE_xXFor women who are not postmenopausal or surgically sterile: agreement to remain abstinent or to use contraceptive methods that result in a failure rate of less than (<) 1% per year during the treatment period for greater than or equal to (>=) 5 months after last dose of Atezo, >= 12 months after last dose of rituximab, >= 12 months after last dose of Pola, and >= 18 months after last dose of obinutuzumabXx_NEWLINE_xXSuspected pulmonary and/or liver metastases (greater >= 10 mm in largest axis)Xx_NEWLINE_xXZubrod performance status equal to or less than 2 (Karnofsky equal to or greater than 50%)Xx_NEWLINE_xXAbsolute neutrophil count greater than or equal to 1,500/microLXx_NEWLINE_xXPlatelets greater than or equal to 100,000/microLXx_NEWLINE_xXPatients must have adequate: i. Bone marrow function: Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl. This ANC cannot have been induced or supported by granulocyte colony stimulating factors. Platelets greater than or equal to 100,000/mcl. ii. Renal function: Creatinine ? 1.5 x institutional upper limit normal (ULN). iii. Hepatic function: Bilirubin ? 1.5 x ULN. SGOT (AST) and SGPT (ALT) ? 3.0 x ULN and alkaline phosphatase ? 2.5 x ULN. iv. Neurologic function: Neuropathy (sensory and motor) less than or equal to Grade 1.Xx_NEWLINE_xXFemale patients must have a bone age of equal to or greater than 12 years of age as determined by local read of appropriate radiographic imagingXx_NEWLINE_xXMale patients must have a bone age of equal to or greater than 14 years of age as determined by local read of appropriate radiographic imagingXx_NEWLINE_xXPlatelets greater than or equal to 100 x 10^9/LXx_NEWLINE_xXSerum creatinine less than or equal to 1.5 x ULN or 24-hour clearance greater than or equal to 50 mL/minXx_NEWLINE_xXPatient who has received radiotherapy within less than or equal to 4 weeks or limited field radiation for palliation within less than or equal to 2 weeks prior to starting study drug, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom greater than or equal to 30% of the bone marrow was irradiatedXx_NEWLINE_xXThe Gleason score should be less than or equal to 7Xx_NEWLINE_xXAdequate bone marrow, liver, and renal function defined as: 1) Absolute neutrophil count (ANC) greater than equal to (>=) 1.5* 10^9cells/litre (L); 2) Platelets >=75 x 109cells/L without transfusion support within 7 days prior to test; 3) Hemoglobin >= 8 gram/deciliter (g/dL) without transfusion support within 7 days prior to test 4) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than equal to (<=) 2.5 * upper limit of normal (ULN) 5) Total bilirubin less than (<) 2 milligram/deciliter (mg/dL) 6) Creatinine determined by serum creatinine levels <=1.5 * ULN or a calculated creatinine clearance of >= 50 mL/min/1.73 m^2Xx_NEWLINE_xXAt the time of randomization, blood counts performed within 4 weeks prior to randomization must meet the following criteria: absolute neutrophil count (ANC) must be greater than or equal to 1500/mm3; Platelet count must be greater than or equal to 100,000/mm3; Hemoglobin must be greater than or equal to 10 g/dL.Xx_NEWLINE_xXSubject must be greater than or equal to 65 years of age in Phase 1 and 2. Subjects enrolled in Cohort C must be either:Xx_NEWLINE_xXgreater than or equal to 75 years of age; ORXx_NEWLINE_xXgreater than or equal to 60 to 74 years will be eligible if the subjects has at least one of the following co-morbidities, which make the subject unfit for intensive chemotherapy:Xx_NEWLINE_xXDLCO less than or equal to 65% or FEV1 less than or equal to 65%;Xx_NEWLINE_xXModerate hepatic impairment with total bilirubin greater than 1.5 to less than or equal to 3.0 × ULNXx_NEWLINE_xXof 0 to 2 for subjects greater than equal to 75 years of ageXx_NEWLINE_xXof 0 to 3 for subjects greater than equal to 60 to 74 years of age, if 0 - 1 another co-morbidity is required to make subject eligible.Xx_NEWLINE_xXGleason score sum of less than or equal to 7Xx_NEWLINE_xXTotal Cumulative Illness Rating Scale (CIRS score) greater than (>) 6Xx_NEWLINE_xXTumor size greater than or equal to 1.0 cm in two perpendicular diametersXx_NEWLINE_xXSerum creatinine less than or equal to 1.5 x ULN or 24-hour clearance greater than or equal to 50 ml/minXx_NEWLINE_xXBaseline LVEF greater than or equal to (>/=) 55%Xx_NEWLINE_xXA visceral metastasis greater than 8 cmXx_NEWLINE_xXPatients with chronic diarrhea or with Grade 2 or greater diarrhea despite appropriate medical management.Xx_NEWLINE_xXPatients must have the following laboratory values: ANC greater than 1500/mcL, platelet count greater than 100,000/mcL, hemoglobin greater than 10 g/dL, bilirubin less than 1.5 x upper limits of normal, AST less than 1.5 x upper limits of normalXx_NEWLINE_xXPatients must have adequate lung function, as defined by oxygen saturation greater than or equal to 90% by pulse oximetryXx_NEWLINE_xXBody surface area (BSA) greater than 0.3 m^2Xx_NEWLINE_xXPreviously treated with 1-3 lines of therapy (example: completed greater than or equal to [>/=] 2 treatment cycles per therapy), including at least one standard chemotherapy-containing regimenXx_NEWLINE_xXAnticipated lifespan greater than 6 month.Xx_NEWLINE_xXAt the time of study entry, blood counts performed within 4 weeks prior to study entry must meet the following criteria: absolute neutrophil count (ANC) must be greater than or equal to 1000/mm3; Platelet count must be greater than or equal to 100,000/mm3; Hemoglobin must be greater than or equal to 9 g/dLXx_NEWLINE_xXCTCAE v4.0 greater than or equal to grade 2 vomiting related to metastatic disease.Xx_NEWLINE_xXGreater than or equal to 10 mm of cervical stromal invasionXx_NEWLINE_xXNo prior use of ketoconazole for greater than 7 daysXx_NEWLINE_xXMale or female subjects aged greater than or equal to (>=) 20 yearsXx_NEWLINE_xXUntreated AML, greater than or equal to 60 years of age and are not candidates for standard therapy due to age, performance status, and/or adverse risk factors, according to the treating physician and with approval of the Medical Monitor;Xx_NEWLINE_xXAbsolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L (greater than or equal to 1500/mm^3)Xx_NEWLINE_xXHemoglobin (Hb) greater than or equal 8.5 g/dLXx_NEWLINE_xXPrior intolerance of irinotecan or necessity for dose reduction greater than 20%Xx_NEWLINE_xXCorrected pulmonary diffusion capacity of greater than or equal to 50%Xx_NEWLINE_xXBcr-Abl level by PCR must be less than or equal to 0.1% and greater than 0.0032% by PCR reported on the International scale. This will be confirmed during screeningXx_NEWLINE_xXAny unresolved toxicity greater or equal to grade 2 from previous anticancer therapy, except for stable chronic toxicities not expected to resolveXx_NEWLINE_xXPrior myeloablative transplant containing full dose TBI (greater than 8 Gy)Xx_NEWLINE_xXPatients taking greater than 12 mg daily of dexamethasoneXx_NEWLINE_xXShortening fraction greater than or equal to 25%Xx_NEWLINE_xXPulse oximetry greater than or equal to 92% on room airXx_NEWLINE_xXQTcF interval greater than 500 msecs at the time of transition to this study.Xx_NEWLINE_xXPatients must have an estimated survival greater than or equal to 3 monthsXx_NEWLINE_xXHas measurable disease (at least one lesion, not irradiated within 12 weeks of study randomisation, with longest diameter more or equal 10mm (lymph nodes minimum more or equal 15 mm) with CT or MRI).Xx_NEWLINE_xXHistory of grade 3 (Gr. 3) or greater retinopathy or keratitisXx_NEWLINE_xXTumors measuring greater than 20mm in diameterXx_NEWLINE_xXCumulative anthracycline exposure greater than 200 mg/m^2 doxorubicin isotoxic equivalentsXx_NEWLINE_xXAdequate organ function, defined as follows: 8.1. Electrocardiogram (ECG) without significant anomalies, performed in the 7 days preceding entry 8.2. Haemoglobin greater than or equal to 90 g/L 8.3. Total white blood cell count (WBC) greater than or equal to 3.0 x 10^9/L 8.4. Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L 8.5. Platelet count greater than 100 x 10^9/L 8.6. Total bilirubin less than or equal to 1.5 fold the maximum normal value at the place of evaluation or 2.5 fold the maximum normal value in case of liver metastases 8.7. Glutamic-oxaloacetic transaminase/aspartate aminotransferase (GOT/AST), and glutamic-pyruvic transaminase/alanine aminotransferase (GPT/ALT), less than or equal to 2.5 fold the maximum normal value at the place of evaluation (in case of liver metastasis, less than 5 fold the maximum normal value) 8.8. Creatinine less than or equal to 2 mg/dL (less than or equal to 176 µmol/L)Xx_NEWLINE_xXPatients with more than 2 (i.e., 3 or greater) uncontrolled or untreated extracranial sites of gross diseaseXx_NEWLINE_xXBilirubin less than or equal to 3.0 mg/dL (unless considered tumor related)Xx_NEWLINE_xXSerum albumin greater or equal to 3 g/dl (CTCAE 4.0 grade 1 abnormality is acceptable)Xx_NEWLINE_xXAdequate bone marrow function as evidenced by ANC greater than 1.5 x 10^9/L, hemoglobin greater than 10.0 g/dL, and platelet count greater than 100 x 10^9/L.Xx_NEWLINE_xXSerum magnesium greater than or equal to 1.8 mg/dLXx_NEWLINE_xXLost greater than or equal to 10% of body weight in the 3 months proceeding signing the ICFXx_NEWLINE_xXLymphocyte count greater than or equal to 700/mcLXx_NEWLINE_xXShortening fraction greater than or equal to 28% by echocardiogram ORXx_NEWLINE_xXHistory of hemoptysis (greater than or equal to 1/2 teaspoon of bright red blood per episode) within 1 month prior to day 1Xx_NEWLINE_xXPatients with evidence of spontaneous hemorrhage greater than 0.5 cm unrelated to surgeryXx_NEWLINE_xXSubject has a grade II or greater peripheral vascular diseaseXx_NEWLINE_xXThe resection cavity must have a maximum diameter of less than or equal to 4 cm; this criteria will be determined by the study radiologist)Xx_NEWLINE_xXGreater than +1 proteinuria on two consecutive dipsticks taken no less than 1 week apartXx_NEWLINE_xXTreating physician assesses tumor to be sufficiently distant from sensitive structures to be able to achieve greater than or equal to 66 Gray (Gy) (i.e., spinal cord tolerance respected in vertebral body metastisisXx_NEWLINE_xXPatients with a creatinine greater than 2.5 times the upper limit of normal are eligible, but will be told that they are at greater risk for kidney damage that could possibly result in temporary or even permanent dialysisXx_NEWLINE_xXDONOR: Children greater than or equal to 12 years of age who have not provided informed assent in the presence of a parent and an attending physician who is not a member of the recipient’s care teamXx_NEWLINE_xXDONOR: Children greater than or equal to 12 years of age who have inadequate peripheral vein access to safely undergo apheresisXx_NEWLINE_xXMust be greater than or equal to 18 years at the time of signing the informed consent form.Xx_NEWLINE_xXGreater than or equal to Grade-2 neuropathyXx_NEWLINE_xXAge greater than or equal to 1 year but less than or equal to 55 years (myeloablative regimen 4); eligibility for pediatric patients will be determined in conjunction with an MD Anderson Cancer Center (MDACC) pediatrician; patients > 55 but < 65 years who have a performance status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s)Xx_NEWLINE_xXAge greater than 55 years and less than or equal to 80 years (nonmyeloablative regimen 2)Xx_NEWLINE_xXAge greater than or equal to 1 but less than or equal to 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive total body irradiation (TBI) may receive reduced intensity regimen 3Xx_NEWLINE_xXMeets UCSF criteria: a single lesion less than or equal to 6.5 cm in diameter or 2-3 lesions less than or equal to 4.5 cm with total tumor diameter less than or equal to 8 cm.Xx_NEWLINE_xXA discrete hepatic artery feeding the tumor with diameter of the vessels equal to or greater than 1.5 mm.Xx_NEWLINE_xXEvidence of myeloid engraftment defined by absolute neutrophil count greater than or equal to (>=) 0.5*109/liter (L) on 3 consecutive days.Xx_NEWLINE_xXGroup 1: Patients must have 1) both a and b below; and 2) at least one of c, d or e:\r\n* a. diffuse cutaneous scleroderma with skin score of greater than or equal to 16 (modified Rodnan scale [mRSS])\r\n* b. duration of systemic sclerosis less than or equal to 7 years from the onset of first non-Raynaud’s symptom\r\n* c. presence of interstitial lung disease (either forced vital capacity [FVC] or corrected diffusing capacity of the lung for carbon monoxide [DLCOcorr] less than 70 % of predicted) and evidence of alveolitis (abnormal bronchoalveolar lavage (BAL) or high resolution chest computed tomography [CT] scan) after treatment with intravenous cyclophosphamide greater than or equal 2 grams given over at least a 3 month period; for patients not able to adequately complete pulmonary function tests (PFT), there must be evidence of progressive disease on chest CT\r\n* d. left heart failure with left ventricular ejection fraction (LVEF) < 50% (that has responded to treatment targeted to scleroderma); 2nd or 3rd atrioventricular (AV) block with other evidence of cardiomyopathy related to SSc; myocardial disease not secondary to SSc must be excluded by a cardiologist \r\n* e. history of SSc-related renal disease that is not active at the time of screening; history of scleroderma hypertensive renal crisis is included in this criterionXx_NEWLINE_xXGroup 2: Progressive pulmonary disease as defined by a decrease in the FVC or DLCOcorr by 15 percent or greater compared to a prior FVC or DLCOcorr in the previous twelve month period; in addition, patients may have either less skin involvement than group 1 (mRSS less than 16) and the FVC or DLCOcorr is less than 70% or both FVC and DLCOcorr greater than or equal to 70% if they have diffuse cutaneous disease (mRSS greater than 16) at screening for the study; patients must also have evidence of alveolitis as defined by abnormal chest CT or BAL; for patients not able to adequately complete PFT, there must be evidence of progressive disease on chest CTXx_NEWLINE_xXGroup 5: Diffuse scleroderma with disease duration less than or equal to 2 years since development of first sign of skin thickening plus modified Rodnan skin score greater than or equal to 25 plus erythrocyte sedimentation rate (ESR) > 25 mm/1st hour and/or hemoglobin (Hb) < 11 g/dL, not explained by causes other than active sclerodermaXx_NEWLINE_xXRefractory disease after first or greater relapse and a re-induction attempt, ORXx_NEWLINE_xXSerum sodium greater than 120 mmol/LXx_NEWLINE_xXFor Post-allo Part B: Transplant must have been performed with active AML (greater than 5% blasts) using a conventional conditioning regimen and have achieved CR or CRi post-alloSCT (with ANC greater than or equal to 1,000 and platelet greater than or equal to 50,000)Xx_NEWLINE_xXPatients with chronic diarrhea of grade 2 or greater despite maximal medical management.Xx_NEWLINE_xXSubject has an ongoing toxicity greater than or equal to grade 3 (NCI CTCAE version 4.03) attributable to prior NSCLC treatment at the time of screening.Xx_NEWLINE_xXHemoglobin greater than or equal to 9 gm/dlXx_NEWLINE_xXBilirubin less than or equal to 1.5 x ULN (CTCAE v4.0 grade 1)Xx_NEWLINE_xXUncontrolled hypertension defined as systolic greater than 180 and diastolic greater than 100Xx_NEWLINE_xXProteinuria CTCAE grade 2 or greaterXx_NEWLINE_xXMust be greater or equal to 20 years of ageXx_NEWLINE_xXOxygen saturation of greater than or equal to 90% on room airXx_NEWLINE_xXKPS equal to or greater than 70Xx_NEWLINE_xXInternational Prognostic Index (IPI) score greater than or equal to 3 for patients greater than 60 years of age or age-adjusted IPI (aaIPI) score of 2 or 3 for patients less than or equal to 60 years of ageXx_NEWLINE_xXPatients with laboratory findings consistent with grade equal to greater than 3 disseminated intravascular coagulation (DIC) or any grade 2 DIC that does not correctXx_NEWLINE_xXProgressing brain metastases (unless previously treated and stable disease for a period of greater than or equal to 3 months on repeat MRI following definitive treatment).Xx_NEWLINE_xXBilirubin less than or equal to 3 mg/dL within 24 hours of enrollmentXx_NEWLINE_xXSevere neuropathy greater than or equal to grade 2Xx_NEWLINE_xXSevere sensorineural hearing loss greater or equal to grade 2Xx_NEWLINE_xXGrade 3 or greater edema (eg, peripheral, pulmonary)Xx_NEWLINE_xXHistory of Grade 3 or greater thromboembolic events in the prior 12 monthsXx_NEWLINE_xXPatients must have a pretreatment granulocyte count (i.e., segmented neutrophils + bands) of greater than 1,000/Fl, a hemoglobin level of greater than or equal to 9.0 gm/dL and a platelet count of greater than 75,000/dL.Xx_NEWLINE_xXGreater than 3 months since melanoma resection;Xx_NEWLINE_xXHemoglobin greater than or equal to 9.0 g/dLXx_NEWLINE_xXShortening fraction greater than or equal to 25%Xx_NEWLINE_xXPulse oximetry greater than or equal to 92% on room airXx_NEWLINE_xXPrior exposure to greater than 360 mg/m2 doxorubicin or liposomal doxorubicin, greater than 120 mg/m2 mitoxantrone, greater than 90 mg/m2 idarubicin, or greater than 720 mg/m2 epirubicinXx_NEWLINE_xXGreater than 20% aberrant intraepithelial lymphocytes (IEL) as assessed by flow cytometryXx_NEWLINE_xXLung lesion size is greater than 1 cmXx_NEWLINE_xXExpected survival must be three months or greaterXx_NEWLINE_xXHemoglobin greater than or equal to (>=) 9 gram per deciliter (g/dL)Xx_NEWLINE_xXPreviously treated with sorafenib for greater than or equal to 4 weeks and discontinued sorafenib treatment at least 14 days prior to Day 1 due to either intolerance or radiographic progressionXx_NEWLINE_xXPatients must have at least one lesion suitable for perfusion CT; the lesion should be greater than or equal to 3 cm in size in the cranial caudal directionXx_NEWLINE_xXCalculated panel reactive antibody (PRA) greater than 90%Xx_NEWLINE_xX2nd line, 3rd line or greaterXx_NEWLINE_xXGrade greater than equal to (>=) 3 hypertriglyceridemiaXx_NEWLINE_xXThe subject has creatine phosphokinase (CPK) elevation NCI CTCAE grade greater than equal to (>=) 2, and/or a previous history of myositis or rhabdomyolysis.Xx_NEWLINE_xXHas unresolved toxicity of greater than or equal to CTCAE Grade 1 attributed to any prior therapiesXx_NEWLINE_xXBone marrow blasts greater than or equal to 5% for relapsed patients, or greater than or equal to 20% for untreated patientsXx_NEWLINE_xXPatients with chronic diarrhea or with grade 2 or greater diarrhea despite maximal medical management.Xx_NEWLINE_xXGreater than or equal to 75 years of ageXx_NEWLINE_xXParticipants with evidence of electrolyte imbalance greater than or equal to (>/=) Grade 2 which cannot be corrected prior to study initiationXx_NEWLINE_xXFor solid tumor-History or presence of hematological malignancies unless curatively treated with no evidence of disease for greater than or equal to 5 yearsXx_NEWLINE_xXAmbulatory patients greater than or equal to (?) 30 years of ageXx_NEWLINE_xXShortening fraction greater than or equal to 28% by echocardiogram ORXx_NEWLINE_xXLateral pelvic separation greater than 50 cm and/or anterior-posterior separation greater than 35 cm which are incompatible with MR for Calculating Attenuation (MRCAT) reconstructionXx_NEWLINE_xXBilirubin needs to be less than or equal to 1.3 x ULNXx_NEWLINE_xXIn patients > 60 years old, documented LVEF of less than or equal to 45%Xx_NEWLINE_xXA diagnosis of CLL defined by a circulating B-lymphocyte count of greater than or equal to 5,000/uL at study entry or at any time in the past and flow cytometry confirmation of immunophenotype with CD5, CD19, CD20, CD23, CD79b, and surface Ig prior to first dose of study treatment.Xx_NEWLINE_xXA minimum of any one of the following disease-related symptoms must be present: a. Unintentional weight loss greater than or equal to 10% within the previous six months; b. Fevers greater than 100.5°F (38.0°C) for greater than or equal to 2 Weeks without evidence of infection; Or c. Night sweats for more than 1 month without evidence of infection.Xx_NEWLINE_xXKnown central nervous system involvement by CLL. Screening laboratory values: Platelets less than 100 x 109/L (unless due to CLL involvement of the bone marrow). Neutrophils less than 1.5 x 109/L (unless due to CLL involvement of the bone marrow). Serum creatinine greater than 1.5 times the upper limit of normal (ULN); subjects with a serum creatinine greater than 1.5 x ULN will be eligible if the calculated creatinine clearance [Cockcroft, 1976] is greater than or equal to 30 mL/min. Total bilirubin greater than 1.5 times ULN (unless due to liver involvement by CLL or Gilbert's disease). Transaminases greater than 2.5 times ULN.Xx_NEWLINE_xXPatients must be greater than or equal to 18 years old.Xx_NEWLINE_xXCohorts 2 & 3 only: Patients with secondary brain tumors must be greater than or equal to 4 weeks from radiotherapy. Patients with progressive secondary brain tumors will not be enrolled under this protocol following the completion of Cohort 3.Xx_NEWLINE_xXGreater than three prior recurrencesXx_NEWLINE_xXHistory of hemoptysis greater than or equal to (>/=) grade 2 within 3 months of randomizationXx_NEWLINE_xXAbsolute neutrophil count (ANC) greater than or equal to 1,500/mm3 or greater than or equal to 1.5 x 10^9/L.Xx_NEWLINE_xXPlatelet count greater than or equal to 100,000/mm3 or greater than or equal to 100 x 10^9/L.Xx_NEWLINE_xXMales or females aged greater than or equal to 18 years at the time of informed consent.Xx_NEWLINE_xXPositive immunohistochemical staining for WT-1 (greater than 10% of cells)Xx_NEWLINE_xXAbsolute neutrophil count greater than or equal to 1,500/microLXx_NEWLINE_xXPlatelets greater than or equal to 100,000/microLXx_NEWLINE_xXHematologic: Absolute neutrophil count (ANC) greater than or equal to 1.5 x 109/L, platelets greater than or equal to 100 x 109/L, and hemoglobin greater than or equal to 9 g/dL. Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin until 5 days after the erythrocyte transfusion.Xx_NEWLINE_xXRecurrent, unexplained fever of greater than 100.5F (38C) without signs of infectionXx_NEWLINE_xXCTCAE grade 3 or greater peripheral vascular diseaseXx_NEWLINE_xXQTc interval greater than or equal to 480msecs.Xx_NEWLINE_xXweight loss of greater than 10% within the prior 6 monthsXx_NEWLINE_xXAt US sites, patients greater than or equal to 12 years of age may be enrolled. At non-US sites, patients must be greater than or equal to 18 years of age.Xx_NEWLINE_xXSerum bicarbonate greater than or equal to 20 mEq/LXx_NEWLINE_xXHemoglobin greater than or equal to 500/uLXx_NEWLINE_xXAdults or skeletally mature adolescents (ie, radiographic evidence of at least 1 mature long bone [eg, humerus with closed growth epiphyseal plate]) equal or greater than 12 years of ageXx_NEWLINE_xXSerum creatinine level greater than CTC grade 2.Xx_NEWLINE_xXBe diagnosed with PHPT (inappropriate PTH level in the setting of a high or high-normal serum calcium level greater than or equal to 10.0 mg/dL).Xx_NEWLINE_xXPatients with a calcium level greater than 13mg/dL.Xx_NEWLINE_xXPatients must have a serum bilirubin equal to or =< 2.0 mg/dl (isolated hyperbilirubinemia related to Gilbert's disease allowed)Xx_NEWLINE_xXPresence of a metastatic lesion greater than 1 cm in size that is amenable to radiation treatmentXx_NEWLINE_xXTumors greater than 3.0 cm at their widest pointXx_NEWLINE_xXHemoglobin greater than or equal to 9 g/dLXx_NEWLINE_xXGleason score equal to or less than 7Xx_NEWLINE_xXBody mass index equal to or greater than 35Xx_NEWLINE_xXAIM 2: Former smoker greater than 6 monthsXx_NEWLINE_xXPATIENT INCLUSION: Worst pain in the past 2 weeks greater than or equal to 4 on the 0-10 pain scaleXx_NEWLINE_xXThe minimum age from greater than 65, to greater than 55Xx_NEWLINE_xXThe minimum age from greater than 55, to greater than 18Xx_NEWLINE_xXPatient must be opioid-tolerant (greater than or equal to 60 mg morphine or equivalent) and on a stable dose of oral opioids for greater than or equal to 1 week; stable baseline opioid dosage defined as a dosage that does not fluctuate by more than 50% from the average dosage over one week prior to screeningXx_NEWLINE_xXTravel distance greater than 50 milesXx_NEWLINE_xXIf surgery is likely greater than 3 hoursXx_NEWLINE_xXThose who plan on relocating outside the greater Pittsburgh area in the next 3 months of intervention.Xx_NEWLINE_xXWeight loss of greater than 5% in the previous 6 monthsXx_NEWLINE_xXCreatinine value greater than 2.0 for men and 1.5 for womenXx_NEWLINE_xXSmoking history of 30 pack-years or greaterXx_NEWLINE_xXLow lean mass defined as either\r\n* Age- and sex- specific relative lean muscle mass standard deviation scores =< -1.0 OR\r\n* Body fat content greater than or equal to 25% in males or greater than or equal to 35% in femalesXx_NEWLINE_xXHistory of serious mood disorder or attempted suicide as determined by patient’s history and physical and by using the Depression Screening; subjects with a score of greater than 10 or those answering #5 with scores greater than a \0\ will be deemed ineligible to be enrolled on studyXx_NEWLINE_xXGreater or equal to 6 months from last chemotherapy treatmentXx_NEWLINE_xXPatient self-report neuropathy score greater than or equal to 3 on a 0 to 10 numeric scale and/or grade 2 or 3 neuropathy (according to the National Cancer Institute Common Toxicity Criteria 4 point grading scale)Xx_NEWLINE_xXGreater than 6-months post diagnosisXx_NEWLINE_xXPatients scoring greater than 4 on a 0 to 10 scale with regard to sleep troubles or painXx_NEWLINE_xXPatient who eats yogurt equal or more than once a day in the last 3 daysXx_NEWLINE_xXPATIENTS: Previously screened and with greater than 0 level of psychological distressXx_NEWLINE_xXSymptomatic patients with a BFI symptom scale of 2 points or greaterXx_NEWLINE_xXSubjects with hemoglobin values at the screening visit equal to or greater than 12.0 g/dLXx_NEWLINE_xXBody mass index (BMI) greater than or equal to 30 kg/m^2Xx_NEWLINE_xXPatients with BMI greater than or equal to 30 kg/m^2 who are undergoing hormonal treatment of endometrial cancerXx_NEWLINE_xXGreater than 25% of blasts must be CD33 positive.Xx_NEWLINE_xXGreater than 25% of blasts must be CD33 positive.Xx_NEWLINE_xXGreater than or equal to grade 2 dry mouth prior to chemoradiotherapy or greater than or equal to grade 2 mucositisXx_NEWLINE_xXAdequate serum folate (greater than or equal to 2 ng/mL) and vitamin B12 (greater than or equal to 200 pg/mL) levels assessed by central laboratory (supplementation and retest acceptable) during screening.Xx_NEWLINE_xXPatient must have adequate kidney function as measured by eGFR greater than or equal to 50 calculated from a standard care serum creatinine performed within 30 days prior to the PN; patient must be able to give written informed consentXx_NEWLINE_xXPatient has grade 2 or greater hypo-albuminemia, serum sodium greater than 150 meq/L, serum osmolality greater than 300 mOsm/kg or blood urea nitrate/serum creatinine ratio greater than 25, within 7 days of screeningXx_NEWLINE_xXEndorse a moderate level of anxiety (e.g., greater than or equal to 8 on the Hospital Anxiety and Depression Scale [HADS-A])Xx_NEWLINE_xXMini Mental State Exam score greater than or equal to 19Xx_NEWLINE_xXRequiring greater than or equal to 180 mg of morphine per dayXx_NEWLINE_xXReceiving a dose of radiation therapy greater than or equal to 6000 centigray (cGy) to one third of the oral cavityXx_NEWLINE_xXProthrombin time greater than 50% of controlXx_NEWLINE_xXRisk of cancer greater than 60% or less than 20%Xx_NEWLINE_xXweight of less than or equal to 45 kg (for sites using cefuroxime only).Xx_NEWLINE_xXCarbon monoxide (CO) level of 5 ppm or greater, confirming smoking statusXx_NEWLINE_xXSubjects taking long-term systemic steroids defined as greater than 3 months in the past 12 monthsXx_NEWLINE_xXLocated in the greater Cleveland metropolitan areaXx_NEWLINE_xXLive in the greater Kansas City metropolitan areaXx_NEWLINE_xXLive in the greater Kansas City metropolitan areaXx_NEWLINE_xXBody mass index (BMI) > or equal to 25 kg/m^2Xx_NEWLINE_xXHeart rate greater than or equal to -105 beats per minute (bpm), or below 45 bpm (one re-screen allowed)Xx_NEWLINE_xXSmoking 5 or more cigarettes, little cigars or cigarillos per day, on average, within the 2 months preceding the screening visit and expired carbon monoxide (CO) greater than or equal to 6 parts per million (ppm); (if < 6, then NicAlert Strip > 2)Xx_NEWLINE_xXWeight loss greater than 10% in prior 4 weeksXx_NEWLINE_xXHave a body mass index (BMI) of 25 kg/m^2 or greater and weight =< 400 lbsXx_NEWLINE_xXCurrent heavy alcohol consumption (greater than or equal to 6 drinks/day, 6 days/week)Xx_NEWLINE_xXParticipants must have either sputum cytologic atypia of mild dysplasia or greater or a history of bronchial biopsy with mild or greater dysplasia within the past 12 monthsXx_NEWLINE_xXSmoking 5 or more cigarettes, little cigars or cigarillos per day, on average, within the 2 months preceding the screening visit and expired carbon monoxide (CO) greater than or equal to 6 parts per million (ppm) (if =< 5, then NicAlert strip > 2)Xx_NEWLINE_xXAfrican-American postmenopausal women with waist circumference greater than 35 inches (88 cm), 5-year invasive breast cancer risk is greater than 1.40% using the Contraceptive and Reproductive Experience (CARE) model, and have at least one of the following:\r\n* Elevated fasting glucose is greater than or equal to 100 mg/dL\r\n* Elevated blood pressure is greater than or equal to 130/85 mm/HgXx_NEWLINE_xXHas been admitted to the hospital greater than three daysXx_NEWLINE_xXCurrent moderate-to-heavy smoker as determined by:\r\n* Has smoked greater than or equal to 10 cigarettes per day regularly for the past year (by history) (greater than or equal to 5 cigarettes per day for study 2) and,\r\n* Has an expired carbon monoxide (CO) at screening visit of 8 ppm or more (6 ppm or more for study 2)Xx_NEWLINE_xXHave a Khorana thromboembolic risk Score greater than or equal to (>=) 2Xx_NEWLINE_xXOverweight or obese (body mass index [BMI] of 24 or greater)Xx_NEWLINE_xXHearing loss greater than grade 1Xx_NEWLINE_xXHave a body mass index (BMI) of 25 kg/m^2 or greaterXx_NEWLINE_xXPatients with an existing local or systemic infection as defined by evidence of fever (a body temperature greater than or equal to 38.0° Celsius (C) with two readings taken at least 10 minutes apart or one body temperature greater than or equal to 38.3°) and any of the following within 24 hours of enrollment: (a) pulse rate greater than or equal to 100 beats/min; (b) respiratory rate greater than or equal to 20/min; (c) white blood cell (WBC) count greater than or equal to 12,000/mm, less than or equal to 4,000/mm or differential count showing greater than 10% band forms; (d) systolic blood pressure less than or equal to 90 mm HgXx_NEWLINE_xXPatients with focal liver observations less than 5 mm or greater than 5 cm in sizeXx_NEWLINE_xXIntermediate to high-risk disease, defined as one of the following factors: PSA > 10, T2b or greater, or a Gleason score of 7 or greaterXx_NEWLINE_xXT1 post contrast lesion size greater than or equal to 10 mmXx_NEWLINE_xXNo chemotherapy for at least 4 weeks and no radiation to the index lesion or clear progression in that lesion (greater than 20% increase in longest diameter)Xx_NEWLINE_xXHEALTHY VOLUNTEER: Must have a body mass index (BMI) greater or equal to 19 and less than or equal to 33Xx_NEWLINE_xXGreater than 400 pounds in weightXx_NEWLINE_xXMetastatic spinal lesions 1 cm or greater in diameterXx_NEWLINE_xXGreater than 4 cores positive, of any Gleason score, on the University of Miami (UM) reviewXx_NEWLINE_xXGreater than 2 cores positive for Gleason 3+4 cancerXx_NEWLINE_xXPatients being considered for RALP and pelvic lymphadenectomy with life expectancy greater than 10 years as determined by treating physicianXx_NEWLINE_xXPatient with metastatic brain tumors greater than or equal to 1.0 cm that will be treated with stereotactic radiosurgery and scheduled for an MRI scan as part of their routine careXx_NEWLINE_xXBody weight greater than 350 lbs (158 Kg)Xx_NEWLINE_xXNodule to be biopsied is greater than 3.0 cm in maximum diameter;Xx_NEWLINE_xXBe diagnosed with T1 or greater LABC, any N and M0.Xx_NEWLINE_xXGreater than T3 disease in past and/or treated with prostatectomyXx_NEWLINE_xXEvidence of QT prolongation on pretreatment electrocardiography (ECG) (greater than 440 ms in males or greater than 450 ms in females)Xx_NEWLINE_xXHEALTHY VOLUNTEERS: Age greater than or equal to 18Xx_NEWLINE_xXCandidates with prostate specific antigen (PSA) greater than 20, digital rectal exam consistent with disease outside the prostate (clinical T3/T4 disease), or Gleason score 8 or greater, should have a bone scan and diagnostic pelvic CT or MRI to exclude metastatic disease; these must be performed within 90 days of registrationXx_NEWLINE_xXBody weight greater than 350 lbs (158 Kg)Xx_NEWLINE_xXGROUP A (painful neuropathy group): Must have subjective symptoms of painful peripheral neuropathy (burning, stabbing, throbbing, painful tingling, aching in the fingers and/or toes) that is greater than or equal to 10 on a scale of 0 to 100 in the neuropathic pain questionnaireXx_NEWLINE_xXPatients with body mass index (BMI) greater than 34 or less than 16Xx_NEWLINE_xXBody mass index (BMI) greater than or equal to 40 or less than or equal to 17 kg/m^2 at screening visitXx_NEWLINE_xXBody mass index of 30 or greaterXx_NEWLINE_xXChronic use of non-steroidal anti-inflammatory drugs (NSAIDs) or omega-3 free fatty acid supplementation within the last 60 days (defined as greater than or equal to 7 consecutive days)Xx_NEWLINE_xXBody weight greater than 400 pounds (limit of Tanita scale)Xx_NEWLINE_xXLife expectancy (in the opinion of the investigator) of greater than or equal to (>=) 12 weeks and LDH levels less than or equal to (<=) 2.5 ULNXx_NEWLINE_xXPatients with plasma alanine aminotransferase greater than 40 IU/dLXx_NEWLINE_xXPatients with plasma aspartate aminotransferase greater than 45 IU/dLXx_NEWLINE_xXGreater than 1.5 x the ULN for blood urea nitrogen (BUN)Xx_NEWLINE_xXClinically or radiologically measurable disease in the breast after diagnostic biopsy, defined as longest diameter greater than or equal to 2.0 cmXx_NEWLINE_xXRadiographically or clinically measurable disease with greater than or equal to (>=) 1 target lesion per IWG criteria for malignant lymphoma.Xx_NEWLINE_xXCriteria 4, Participants have measurable disease which is equal to one or more metastatic liver lesions that can be accurately and serially measured that are greater than or equal to 1 cm dimension and for which the longest diameter is greater or equal to 1 cm as measured by CT (Computed Tomography) scan or magnetic resonance imaging. The metastatic liver lesion(s) must not be in an area that received prior localized therapies.Xx_NEWLINE_xXPatients with body mass index greater than 40 kg/m^2Xx_NEWLINE_xXThe participant has adequate hematologic function as defined by absolute neutrophil count greater than or equal to 1500/microliter (?L), hemoglobin greater than or equal to 9 grams/deciliter (g/dL), and platelet count greater than or equal to 100,000/?L.Xx_NEWLINE_xXThe participant has adequate hematologic function as defined by absolute neutrophil count greater than or equal to 1500/microliter (?L), hemoglobin greater than or equal to 9 grams/deciliter (g/dL), and platelet count greater than or equal to 100,000/?L.Xx_NEWLINE_xXDisease progression or recurrence less than or equal to 12 months of prior autologous SCTXx_NEWLINE_xX